Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07241260

Hydrate Heroes for Improving Brain Function & Mood

The primary goal of this 12-week randomized controlled study is to evaluate whether daily use of Hydrate Heroes results in measurable improvements in brain activity, mental health, and performance on cognitive tasks. By analyzing brainwave data, physical response metrics, and patient-reported outcomes, the study will demonstrate whether the supplement produces meaningful effects on mental and neurological health.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of South Florida

Tampa, Florida, 33620, United States

About this study

The study will utilize electrophysiological measurements of the brain and body.

EEG recordings will be captured using the Emotiv FLEX 2.0 wireless headset, which measures brainwave activity across 32 electrode sites using a standard 10-10 system. EEG data will be collected at 256 Hz and analyzed using EEGLAB software to assess spectral power and topographic changes over time. The protocol includes 20 minutes of EEG testing per session, with specific tasks designed to elicit measurable cognitive responses.

Participants will wear an Empatica Embrace wristband during testing to collect physiological data including motion, stress indicators, and heart rate variability.

Participants will complete a series of validated tests on an iPad while wearing the EEG headset and wrist device. Tasks include:

  • Grandfather Passage (speech task)
  • Card Matching (memory and attention)
  • Boston Naming Test (language)
  • Finger Tapping (motor speed)
  • Trail Making Test (executive function)
  • Dual-Task Performance (cognitive load)

Over 500 digital data features will be captured per session using a system that combines inputs from device sensors (e.g., gyroscope, camera, microphone) with user interactions (e.g., tapping, speech, app use).

Participants will complete standardized questionnaires, including PROMIS-29+2 and IPAQ-SF, to assess aspects such as emotional well-being, physical activity, fatigue, and pain. The PROMIS-29+2 is aA collection of short forms or computer adaptive tests containing a fixed number of items from seven PROMIS domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities) The PROMIS-29+2 is used to calculate a preference score. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). Scores can be used in comparisons across groups and for cost-utility analyses. The profile includes all items in the PROMIS-29 Profile v2.1 plus two Cognitive Function Abilities items. T-scores from the measure can be used to calculate a preference-based score.

International Physical Activity Questionnaire (IPAQ) short form is an 8-item questionnaire that encompasses time spent walking, in moderate and vigorous physical activity. The short form is feasible to administer and shows similar reliability and validity results in comparison to the long form. Test-rest reliability indicates good stability and high reliability (α <.80). Scoring provides a categorization of low, moderate, or high intensity of physical activity. Ideally, this will be performed pre- and post-intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 65 years at time of consent.
  • Fluent in English (able to read, write, speak, and understand English).
  • Generally healthy, without chronic medical conditions (see Exclusion 10.3).
  • Willing and able to attend three in-person study visits over an approximate 12-week period (enrollment, ~6 weeks, ~12 weeks).
  • Willing to consume assigned Hydrate Heroes packets as directed (6 sticks/day, 3 sticks/day, or no supplement for control).
  • Willing to log daily water intake and number of Hydrate Heroes packets consumed in the study's online tracking system.
  • Capable of providing informed consent.

Exclusion criteria

  • Neurological or Psychiatric Conditions
  • History of epilepsy, recurrent seizures, severe head injury, or other significant neurological disorders.
  • Current diagnosis of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, severe major depressive disorder).

· Cardiovascular or Renal Conditions

  • Chronic kidney disease, congestive heart failure, or any condition requiring medically supervised fluid restriction.
  • Documented electrolyte imbalance (e.g., hyponatremia, hypokalemia) within the past 6 months.
  • Medication and Supplement Conflicts
  • Use of medications known to alter EEG readings (e.g., benzodiazepines, antiepileptics, antipsychotics).
  • Use of high-dose diuretics or other drugs that substantially affect hydration status.
  • Concurrent use of any supplements containing one or more key ingredients of Hydrate Heroes - adaptogenic mushroom blends, magnesium, potassium, zinc, vitamin D₃, vitamin C (including Amla), electrolytes, or elderberry - that cannot be safely discontinued for the 12-week study duration.
  • Reproductive Status
  • Pregnant or currently breastfeeding.
  • Compliance Risk
  • Inability or unwillingness to reliably follow the hydration/supplement protocol or complete daily logging.
  • Inability to attend scheduled visits or follow instructions.

Treatment and study plan

Hydrate Heroes (6 packets)

Dietary Supplement

Participants that are randomized to the active comparator groups will receive 6 packets of Hydrate Heroes to use daily.

Hydrate Heroes (3 packets)

Dietary Supplement

Participants that are randomized to the active comparator groups will receive 3 packets of Hydrate Heroes to use daily.

Primary outcomes

  1. Electroencephalography - Frequencies

    Time frame: 12 weeks

    Measurement of brain electrical activity.

    Measures will include power band analysis (e.g., delta, theta, alpha, beta, gamma) summed over activities and comparisons made between groups (i.e. ratios).

  2. Electroencephalography - ERP Amplitude

    Time frame: 12 weeks

    Measurement of brain electrical activity.

    Event-related potentials will be determined from events that occur during the activities. Differences in P300 amplitude will be determined (uV).

  3. Electroencephalograpy - ERP Latency

    Time frame: 12 weeks

    Measurement of brain electrical activity.

    Event-related potentials will be determined from events that occur during the activities. Differences of P300 latency will be determined between groups (msec).

Secondary outcomes

  1. Patient Reported Outcomes Measurement Information System (PROMIS)-29 + 2

    Time frame: 12 weeks

    This single form patient reported outcome provides insight to pain, depression, anxiety, sleep, and physical function.

    Score will be reported as a t-score. The average t-score is 50. Deviation from 50 demonstrates magnitude of difference in either positive or negative direction.

  2. International Physical Activity Questionnaire - Short Form (IPAQ-SF)

    Time frame: 12 weeks

    Patient reported outcome of physical activity over a 7-day period. The scores provide both a categorical output of 'Inactive', 'Slightly Active', and 'Active' and a continuous variable of metabolic equivalent (MET).

Study contacts

Contact information is provided by the study sponsor or research team.

Katherine F Walters, MS

CONTACT

[email protected]

813-974-1377

Nathan D Schilaty, DC, PhD

CONTACT

[email protected]

813-974-1377

Sponsors and collaborators

Lead sponsor

University of South Florida

Other

Registry information

Official study title

Boosting Brain and Mood: Exploring the Impact of Hydrate Heroes on Mental Health and Brain Activity

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 21, 2025
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.